| [1] |
胡盛寿，高润霖，刘力生，等．《中国心血管病报告2018》概要 [J]．中国循环杂志，2019，34(3): 209-220.
|
| [2] |
魏之瑶，钱海燕．新型冠状病毒肺炎患者的心肌损伤表现[J/OL]．中华心血管病杂志，2020，48(6): 439-442.
|
| [3] |
中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组．新型冠状病毒肺炎流行病学特征分析 [J]．中华流行病学杂志，2020，41(2): 145-151.
|
| [4] |
廖玉华，程翔，曾秋棠，等．湖北省新型冠状病毒肺炎疫情下心血管病治疗与管理专家建议[J]．临床心血管病杂志，2020，36(3): 201-203.
|
| [5] |
Zhou P, Yang XL, Wang XG，et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin [J]．Nature，2020(579): 270-273.
|
| [6] |
Zhao Y, Zhao ZX, Wang YJ，et al.Single cell RNA experssion profiling of ACE2 the putative receptor of Wuhan 2019-nCov [J/OL]．bioRxiv，2020.[2020-04-11]．published online ahead of print January 26，2020]
URL
|
| [7] |
Harmer D, Gilbert M, Borman R，et al.Quantitative mRNA expression profiling of ACE 2，a novel homologue of angiotensin [J]．FEBS Lett，2002，532(1-2): 107-110.
|
| [8] |
Tipnis SR, Hooper NM, Hyde R，et al.A human homolog of angiotensin-converting enzyme.Cloning and functional expression as a captopril-insensitive carboxypeptidase [J]．J Biol Chem，2000，275(43): 33238-33243.
|
| [9] |
Vinturache AE, Smith FG.Angiotensin type 1 and type 2 receptors during ontogeny; cardiovascular and renal effects [J]．Vascul Pharmacol，2014，63(3): 145-54.
|
| [10] |
Chow BS, Allen TJ.Angiotensin Ⅱ type 2 receptor (AT2R) in renal and cardiovascular disease [J]．Clin Sci (Lond)，2016，130(15): 1307-1326.
|
| [11] |
Meng Y, Yu CH, Li W，et al.Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-κB pathway [J]．Am J Respir Cell Mol Biol，2014，50(4): 723-36.
|
| [12] |
Ye R, Liu Z．ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway [J]．Exp Mol Pathol，2019(113): 104350.
|
| [13] |
Solinski HJ, Gudermann T, Breit A．Pharmacology and signaling of MAS-related G protein-coupled receptors [J]．Pharmacol Rev，2014，66(3): 570-597.
URL
|
| [14] |
Keidar S, Kaplan M, Gamliel-Lazarovich A．ACE2 of the heart：from angiotensin ito angiotensin(1-7) [J]．Cardiovasc Res，2007，73(3): 463-469.
|
| [15] |
Dahlöf B, Lindholm LH, Hansansson L，et al.Morbidity and mortality in the swedish trial in old patients with hypertension (ST0P-Hypertension) [J]．Lancet，1991，338(8778): 1281-1285.
|
| [16] |
Thomopoulos C, Parati G, Zanchetti A．Effects of blood pressure lowering on outcome incidence in hypertension：4.Effects of various classes of antihypertensive drugs-overview and meta-analyses[J]．J Hypertens，2015，33(2): 195-211.
|
| [17] |
Gottlieb SS, Mc Carter RJ, Vogel RA.Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infaretion [J]．N Engl J Med，1998，339(8): 489-497.
|
| [18] |
Ellis K, Tcheng JE, Sapp S，et al.Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention：pooled results from the Epic，Epilog，Epistent，Capture and Rapport Trials [J]．J Interv Cardiol，2003，16(4): 299-305.
|
| [19] |
Chatterjee S, Chaudhuri D, Vedanthan R，et al.Early intravenous beta-blockers in patients with acute coronary syndrome-a meta-analysis of randomized trials[J]．Int J Cardiol，2013，168(2): 915-921.
URL
|
| [20] |
Frishman WH.Beta-adrenergic receptor blockers in hypertension：alive and well[J]．Prog Cardiovasc Dis，2016，59(3): 247-252.
|
| [21] |
应用β肾上腺素能受体阻滞剂规范治疗冠心病中国专家共识组．应用β肾上腺素能受体阻滞剂规范治疗冠心病的中国专家共识[J]．中国循环杂志，2020，35(2): 108-123.
|
| [22] |
CIBIS-II Investigators and Committees.The Cardiac Insufficiency Bisoprolol Study Ⅱ(CIBIS-Ⅱ)：a randomised trial [J]．Lancet，1999(353): 9-13.
|
| [23] |
Packer M, Coats AJ, Fowler MB，et al.Effect of carvediol on survival in severe chronic heart failure[J]．N Engl J Med，2001(344)：1651-1658.
|
| [24] |
罗洁，曹娟，陈丽，等．β受体阻滞剂治疗射血分数保留心力衰竭疗效的Meta分析[J]．临床心血管病杂志，2019，35(11): 1011-1017.
|
| [25] |
Lpez-Sendn J, Swedberg K, McMurray J，et al.Expert consensus document on beta-adrenergic receptor blockers [J]．Eur Heart J，2004(25): 1341-1362.
|
| [26] |
Egred M, Shaw S, Mohammad B，et al.Under-use of beta-blockersin patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease[J]．QJM，2005，98(7): 493-497.
|
| [27] |
Peacock A, Ross K．Pulmonary hypertension：a contraindication to the use of{beta}-adrenoceptor blocking agents[J]．Thorax，2010，65(5): 454-455.
|
| [28] |
Dransfield MT, Rowe SM, Johnson JE，et al.Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD [J]．Thorax，2008，63(4): 301-305.
|
| [29] |
Chatterjee S, Biondi-Zoccai G, Abbate A，et al.Benefits of β blockers in patients with heart failure and reduced ejection fraction：network meta-analysis [J]．BMJ，2013(346): f55.
|
| [30] |
Short PM, Lipworth SI, Elder DH，et al.Effect of beta blockers in treatment of chronic obstructive pulmonary disease：a retrospective cohort study [J]．BMJ，2011(342): d2549.
|
| [31] |
Rutten FH, Zuithoff NP, Hak E，et al.Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease [J]．Arch Intern Med，2010，170(10): 880-887.
|
| [32] |
Ekström MP, Hermansson AB, Strom KE.Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease [J]．Am J Respir Crit Care Med，2013，187(7): 715-720.
|
| [33] |
Galiè N, Humbert M, Vachiery JL，et al.2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension [J]．Rev Esp Cardiol (Engl Ed)，2016，69(2): 177.
|
| [34] |
Bandyopadhyay D, Bajaj NS, Zein J，et al.Outcomes of β-blocker use in pulmonary arterial hypertension：a propensity-matched analysis[J]．Eur Respir J，2015，46(3): 750-760.
|
| [35] |
Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure [J]．Circulation，2000，101(5): 558-569.
|
| [36] |
Rubin LJ. The beta-adrenergic receptor in pulmonary arterial hypertension：a novel therapeutic target？[J]. J Am Coll Cardiol，2015，65(7): 681-683.
|
| [37] |
Perros F, Ranchoux B, Izikki M, et al. Nebivolol for improving endothelial dysfunction，pulmonary vascular remodeling，and right heart function in pulmonary hypertension[J]．J Am Coll Cardiol，2015，65(7): 661-683.
|
| [38] |
Malenfant S, Perros F．β-blockers in pulmonary arterial hypertension：generation might matter[J]．Eur Respir J，2016，47(2): 682-684.
|
| [39] |
Rubin LJ.The adrenergic nervous system as a therapeutic target in pulmonary arterial hypertension：a cautionary tale[J]．Eur Respir J，2016，48(3): 617-618.
|
| [40] |
Guan WJ, Ni ZY, Hu Y，et al.Clinical characteristics of coronavirus disease 2019 in China[J]．N Engl J Med，2020，382(18): 1708-1720.
|
| [41] |
杨策．新型冠状病毒肺炎诊治——殊死搏斗中的困境与挑战[J/CD]．中华诊断学电子杂志，2020，8(1): 1-8.
|
| [42] |
陈韵岱，薛浩．新型冠状病毒肺炎合并心血管疾病的临床问题探讨[J]．中国介入心脏病学杂志，2020，28(2): 107-109.
|